Danai Daliani

4.9k total citations
53 papers, 2.9k citations indexed

About

Danai Daliani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Danai Daliani has authored 53 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Danai Daliani's work include Prostate Cancer Treatment and Research (15 papers), Renal cell carcinoma treatment (7 papers) and Peptidase Inhibition and Analysis (6 papers). Danai Daliani is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), Renal cell carcinoma treatment (7 papers) and Peptidase Inhibition and Analysis (6 papers). Danai Daliani collaborates with scholars based in United States, Greece and Spain. Danai Daliani's co-authors include Christos N. Papandreou, Christopher J. Logothetis, Lance C. Pagliaro, Randall E. Millikan, Shi‐Ming Tu, Louis L. Pisters, Peter F. Thall, Sijin Wen, Jeri Kim and Azmi Nabulsi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Danai Daliani

53 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danai Daliani United States 23 1.3k 1.1k 900 805 435 53 2.9k
Shi‐Ming Tu United States 31 1.8k 1.4× 1.4k 1.3× 1.2k 1.3× 996 1.2× 509 1.2× 95 3.6k
Avishay Sella United States 32 1.8k 1.4× 1.2k 1.1× 860 1.0× 1.8k 2.2× 184 0.4× 105 3.6k
Aristotle Bamias Greece 28 792 0.6× 1.9k 1.7× 785 0.9× 855 1.1× 189 0.4× 88 3.3k
Lawrence I. Karsh United States 21 1.8k 1.5× 1.8k 1.6× 520 0.6× 598 0.7× 783 1.8× 113 3.2k
Hiro‐omi Kanayama Japan 35 1.4k 1.1× 1.0k 0.9× 1.9k 2.1× 967 1.2× 105 0.2× 195 4.0k
Lisa Sengeløv Denmark 19 1.1k 0.8× 1.4k 1.3× 581 0.6× 2.1k 2.6× 217 0.5× 45 3.5k
Louis R. Bégin Canada 37 1.7k 1.3× 1.6k 1.5× 1.3k 1.5× 767 1.0× 190 0.4× 104 4.7k
Takashi Karashima Japan 24 790 0.6× 770 0.7× 1.1k 1.2× 558 0.7× 145 0.3× 119 2.3k
Fabio Calabrò Italy 24 950 0.8× 689 0.6× 386 0.4× 680 0.8× 232 0.5× 96 1.9k
Shaobo Zhang United States 37 1.6k 1.2× 511 0.5× 1.6k 1.8× 1.7k 2.1× 100 0.2× 100 3.7k

Countries citing papers authored by Danai Daliani

Since Specialization
Citations

This map shows the geographic impact of Danai Daliani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danai Daliani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danai Daliani more than expected).

Fields of papers citing papers by Danai Daliani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danai Daliani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danai Daliani. The network helps show where Danai Daliani may publish in the future.

Co-authorship network of co-authors of Danai Daliani

This figure shows the co-authorship network connecting the top 25 collaborators of Danai Daliani. A scholar is included among the top collaborators of Danai Daliani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danai Daliani. Danai Daliani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nicolatou‐Galitis, Ourania, Amanda Psyrri, Nikolaos Tsoukalas, et al.. (2023). Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients. SHILAP Revista de lepidopterología. 3(1). 123–133. 2 indexed citations
2.
Dimitropoulos, Konstantinos, Louis L. Pisters, Christos N. Papandreou, et al.. (2023). The Impact of Enhanced Recovery after Surgery Protocol Implementationon Postoperative Pain Management in the Era of Opioid Crisis: The PostchemotherapyOpen RPLND Experience. Current Cancer Drug Targets. 23(11). 910–916. 2 indexed citations
3.
Froudarakis, Μarios E., Eleftheria Hatzimichael, Konstantinos Lagos, et al.. (2013). Revisiting bleomycin from pathophysiology to safe clinical use. Critical Reviews in Oncology/Hematology. 87(1). 90–100. 81 indexed citations
4.
Vlachostergios, Panagiotis J., et al.. (2012). Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer. Journal of Negative Results in BioMedicine. 11(1). 2–2. 7 indexed citations
5.
Voutsadakis, Ioannis A., Panagiotis J. Vlachostergios, Danai Daliani, et al.. (2012). CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy. Urologia Internationalis. 88(2). 158–164. 14 indexed citations
6.
Patrikidou, Anna, Panagiotis J. Vlachostergios, Ioannis A. Voutsadakis, et al.. (2011). Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell International. 11(1). 13–13. 17 indexed citations
7.
Vlachostergios, Panagiotis J., Anna Patrikidou, Ioannis A. Voutsadakis, et al.. (2011). p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naïve Prostate Cancer. Pathology & Oncology Research. 18(2). 245–252. 4 indexed citations
8.
Vlachostergios, Panagiotis J., et al.. (2010). Nonbacterial Thrombotic (Marantic) Endocarditis in a Patient with Colorectal Cancer. Onkologie. 33(8). 3–3. 10 indexed citations
9.
Vlachostergios, Panagiotis J., Anna Patrikidou, Danai Daliani, & Christos N. Papandreou. (2009). The ubiquitin‐proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation. Journal of Cellular and Molecular Medicine. 13(9b). 3019–3031. 15 indexed citations
10.
Mao, Shifeng, Danai Daliani, Xuemei Wang, et al.. (2007). Employing the treatment‐free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. The Prostate. 67(15). 1677–1685. 3 indexed citations
11.
Mathew, Paul, Christopher J. Logothetis, P. Dieringer, et al.. (2006). Thalidomide/Estramustine/Paclitaxel in Metastatic Androgen-Independent Prostate Cancer. Clinical Genitourinary Cancer. 5(2). 144–149. 10 indexed citations
12.
Daliani, Danai, Vasily J. Assikis, Shi‐Ming Tu, et al.. (2003). Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma. Cancer. 97(3). 561–567. 21 indexed citations
13.
Logothetis, Christopher J., Kenneth K. Wu, Laury Finn, et al.. (2001). Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.. PubMed. 7(5). 1198–203. 117 indexed citations
14.
Tu, Shi‐Ming, Randall E. Millikan, Ebrahim S. Delpassand, et al.. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. The Lancet. 357(9253). 336–341. 277 indexed citations
15.
Daliani, Danai, Clotilde M. Jackow, William Pugh, et al.. (1998). Tumor Necrosis Factor-α and Interferon-γ, but not HTLV-I Tax, are Likely Factors in the Epidermotropism of Cutaneous T-Cell Lymphoma via Induction of Interferon-Inducible Protein-10. Leukemia & lymphoma. 29(3-4). 315–328. 25 indexed citations
16.
Daliani, Danai, et al.. (1997). Phase II study of doxorubicin, etoposide, and cisplatin for patients with small cell carcinoma of the prostate. 38. 429. 1 indexed citations
17.
Dimopoulos, Meletios Α., Danai Daliani, William Pugh, et al.. (1997). Primary Ovarian Non-Hodgkin's Lymphoma: Outcome after Treatment with Combination Chemotherapy. Gynecologic Oncology. 64(3). 446–450. 84 indexed citations
18.
Sarris, Andreas H., Danai Daliani, Mary K. Crow, et al.. (1996). Interferon-Inducible Protein-10 and the Pathogenesis of Cutaneous T-Cell Lymphomas. Leukemia & lymphoma. 24(1-2). 103–110. 9 indexed citations
19.
Daliani, Danai, Donna Weber, & Raymond Alexanian. (1995). Light‐heavy chain deposition disease progressing to multiple myeloma. American Journal of Hematology. 50(4). 296–298. 13 indexed citations
20.
Bafaloukos, Dimitrios, et al.. (1993). First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer. European Journal of Cancer. 29(6). 851–853. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shi‐Ming Tu Breakdown of academic impact, for papers by Avishay Sella Breakdown of academic impact, for papers by Aristotle Bamias Breakdown of academic impact, for papers by Lawrence I. Karsh Breakdown of academic impact, for papers by Hiro‐omi Kanayama Breakdown of academic impact, for papers by Lisa Sengeløv Breakdown of academic impact, for papers by Louis R. Bégin Breakdown of academic impact, for papers by Takashi Karashima Breakdown of academic impact, for papers by Fabio Calabrò Breakdown of academic impact, for papers by Shaobo Zhang
Rankless by CCL
2026